Screener
Sutro Biopharma STRO EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Sutro Biopharma in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Sutro Biopharma’s 10-Q, filed August 12, 2026.
- Filed
- Aug 12, 2026, 7:30 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-345748
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Numerator: | ||||
| Net loss | $(38,533) | $(11,499) | $(77,017) | $(87,467) |
| Denominator: | ||||
| Shares used in computing net loss per share | 16,571,602 | 8,511,985 | 14,836,617 | 8,482,434 |
| Net loss per share, basic and diluted | $(2.33) | $(1.35) | $(5.19) | $(10.31) |
Item 1. Financial Statements.
FAQ
- What is Sutro Biopharma's EPS (diluted)?
- Sutro Biopharma (STRO) reported EPS (diluted) of -$2.33 in Q2 2026.
- How has Sutro Biopharma's EPS (diluted) changed year-over-year?
- Sutro Biopharma's EPS (diluted) decreased by 72.6% year-over-year, from -$1.35 to -$2.33.
- What is the long-term trend for Sutro Biopharma's EPS (diluted)?
- Over 3 years (2021 to 2025), Sutro Biopharma's EPS (diluted) has grown at a 140.6% compound annual growth rate (CAGR), from -$2.29 to -$31.88.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Sutro Biopharma's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude